ChromoCure to Secure Patents on Proprietary Chromosomal Cancer Detection Technology as Foundation in Preparation for [KCNLMGD]
RENO, NV, Jan 27 (MARKET WIRE) --
ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announced today, based
on the recent validation of its cancer detection approach and efficacy of
its proprietary Chromosomal Scanning Technology, that it has retained
Patent & Intellectual Property Attorneys to assess its growing
Intellectual Property portfolio and secure necessary filings and Patent
protections. A complex and innovative series of systems, processes, cell
preparation techniques and diagnostic algorithms are currently integrated
in ChromoCure's landmark Chromosomal Scanning Technology.
The Company recently announced it will accelerate the implementation of
its Cancer Therapy and Cure initiatives. The Intellectual Property audit
and subsequent Patent Applications and protections will provide the
required foundation for various research programs and collaborations.
ChromoCure's chromosomal approach to cancer detection, therapy and cure
has been validated by recent publications, including the Mayo Clinic
findings. Per the publication of the company's clinical collaboration and
testing, its proprietary Chromosomal Scanner technology was demonstrated
a reliable and effective automated technological system to detect
aneuploid cells in real-world specimens, that detection of aneuploid
cells is diagnostic of cervical lesions and that the Chromosomal Scanner
possesses superb performance at not only detecting cancer but achieving
the near theoretical maximum agreement with the collaborating clinic's
error containing data.
The Company's pioneering knowledge of cancer's chromosomal properties
invites very effective, non-toxic therapeutic strategies. ChromoCure's
understanding of cancer's chromosomal peculiarities provides the most
promising avenue for treatment and cure and reinforces its pioneering
status.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems and
technologies. The Company's proprietary ChromoCure CS200 Chromosomal
Scanner system has been proven accurate and efficient in the measurement
of the unique genomic characteristic found in 100% of all cancers and
never found in normal cells. The Company's technology has been proven to
have an effective accuracy of 100% for all cancers at all stages and
believes its technology will become the worldwide gold standard for
cancer detection, progression measurement, and research for both therapy
and cure.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS (and are
incorporated herein by reference) and should be read before any investment
decision.
Contact:
ChromoCure, Inc.
www.ChromoCure.com
info@chromocure.com
Tel 1.775.636.654
Copyright 2010, Market Wire, All rights reserved.
-0-
27Jan10 13:30 GMT
Symbols:
us;KKUR
Source MW MarketWire
Categories:
DRU HEA INW MNG NEWR MST/R MST/R/US MST/L/EN MST/R/US TGT/BGN
